Hanmi Pharm. has entered a licensing agreement with Eli Lilly for the development, manufacturing, and commercialization of its biologic drug candidate Sonefpeglutide. The deal validates the asset and could provide future development and commercial upside for Hanmi. The announcement is positive for both companies, though the immediate market impact is likely limited without disclosed financial terms.
Hanmi Pharm. has entered a licensing agreement with Eli Lilly for the development, manufacturing, and commercialization of its biologic drug candidate Sonefpeglutide. The deal validates the asset and could provide future development and commercial upside for Hanmi. The announcement is positive for both companies, though the immediate market impact is likely limited without disclosed financial terms.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.45
Ticker Sentiment
